Clinical Trial Details

Trial ID: L0447
Source ID: IRCT20140107016123N14
Associated Drug: Pomegranate
Title: The effect of pomegranate extract tablet on some of metabolic factor, hepatokines (fetuin A, FGF21), inflammatory biomarkers, anthropometric indices and grade of fatty liver in patients with non-alcoholic fatty Liver disease
Acronym: --
Status: Recruiting
Study Results: No Results Available
Results: --
Conditions: Nonalcoholic fatty liver disease (NAFLD). <br>Fatty (change of) liver, not elsewhere classified;K76.0
Interventions: Intervention 1: Intervention group: Pomegranate extract tablet 225 mg twice daily for 12 weeks. Intervention 2: Control group: Placebo twice daily for 12 weeks.
Outcome Measures: Alanine aminotransferase. Timepoint: before intervention and after 12 weeks. Method of measurement: seum level.;Aspartate transaminase. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Gamma glutamyl transferase. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Alkaline phosphatase. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Triglycerides. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Total cholesterol. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Low density lipoprotein (LDL). Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;High density lipoprotein (HDL). Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Fasting blood sugar. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Fasting insulin. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Insulin resistance. Timepoint: before intervention and after 12 weeks. Method of measurement: 405??(insulin??glucose)=HOMA-IR ; Homeostatic model assessment.;Adiponectin. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Fetuin A. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Fibroblast growth factor 21(FGF 21). Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Total antioxidant capacity. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;High sensitive C reactive protein (hs-CRP). Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Interlukin-6(IL-6). Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Weight. Timepoint: before intervention and after 12 weeks. Method of measurement: scale.;Waist circumference. Timepoint: before intervention and after 12 weeks. Method of measurement: waist circumference in CM.;Body mass index (BMI). Timepoint: before intervention and after 12 weeks. Method of measurement: Ratio of weight (kg) to second power (in meters).;Degree of hepatic steatosis. Timepoint: before intervention and after 12 weeks. Method of measurement: sonography.Systolic blood pressure. Timepoint: before intervention and after 12 weeks. Method of measurement: Blood pressure monitor.;Diastolic blood pressure. Timepoint: before intervention and after 12 weeks. Method of measurement: Blood pressure monitor.
Sponsor/Collaborators: Ahvaz University of Medical Sciences
Gender: All
Age: 18 years65 years
Phases: Not applicable
Enrollment: 50
Study Type: interventional
Study Designs: Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The present study is a simple randomized clinical trial on subjects with nonalcholic fatty liver. In this study, indiv
Start Date: 04/12/2019
Completion Date: --
Results First Posted: --
Last Update Posted: 17 December 2019
Locations: Iran (Islamic Republic of)
URL: http://en.irct.ir/trial/42739